Orthofix Medical Inc. (NASDAQ:OFIX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Orthofix Medical Inc. (NASDAQ:OFIX) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $21.50.

OFIX has been the topic of several research reports. Stifel Nicolaus began coverage on Orthofix Medical in a report on Tuesday, October 28th. They set a “buy” rating and a $22.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Finally, Barrington Research raised their price target on Orthofix Medical from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th.

Orthofix Medical Trading Up 3.0%

Shares of NASDAQ OFIX opened at $16.20 on Friday. Orthofix Medical has a 1-year low of $10.24 and a 1-year high of $20.48. The company has a 50-day moving average of $15.40 and a two-hundred day moving average of $14.12. The company has a market cap of $641.52 million, a PE ratio of -5.35 and a beta of 0.79. The company has a current ratio of 2.47, a quick ratio of 1.38 and a debt-to-equity ratio of 0.39.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in Orthofix Medical by 67.7% in the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock valued at $333,000 after buying an additional 8,241 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Orthofix Medical during the 1st quarter valued at $1,048,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Orthofix Medical by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock valued at $335,000 after acquiring an additional 1,213 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Orthofix Medical in the 1st quarter valued at $575,000. Finally, Jane Street Group LLC bought a new position in shares of Orthofix Medical in the 1st quarter worth $1,076,000. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.